Paradice Investment Management LLC increased its position in Halyard Health, Inc. (NYSE:HYH) by 2.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,564,813 shares of the medical instruments supplier’s stock after purchasing an additional 31,832 shares during the quarter. Halyard Health makes up 5.3% of Paradice Investment Management LLC’s portfolio, making the stock its 5th largest holding. Paradice Investment Management LLC owned approximately 3.34% of Halyard Health worth $70,464,000 at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new position in Halyard Health during the first quarter worth $727,000. Koch Industries Inc. acquired a new position in Halyard Health during the second quarter worth $297,000. TIAA CREF Investment Management LLC raised its stake in Halyard Health by 35.2% during the second quarter. TIAA CREF Investment Management LLC now owns 202,901 shares of the medical instruments supplier’s stock worth $7,970,000 after acquiring an additional 52,881 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Halyard Health by 3.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 797,993 shares of the medical instruments supplier’s stock worth $31,346,000 after acquiring an additional 27,421 shares in the last quarter. Finally, Sterling Capital Management LLC acquired a new position in Halyard Health during the second quarter worth $631,000. 90.28% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have issued reports on HYH shares. TheStreet lowered Halyard Health from a “b-” rating to a “c+” rating in a research note on Monday, October 30th. Zacks Investment Research lowered Halyard Health from a “buy” rating to a “sell” rating in a research note on Wednesday, October 4th. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. KeyCorp reiterated a “hold” rating on shares of Halyard Health in a research note on Tuesday, October 17th. Finally, Deutsche Bank increased their price objective on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Halyard Health presently has a consensus rating of “Buy” and a consensus target price of $44.00.
Shares of Halyard Health, Inc. (NYSE HYH) traded down $0.06 during trading hours on Tuesday, hitting $46.85. The stock had a trading volume of 152,100 shares, compared to its average volume of 347,488. Halyard Health, Inc. has a 52 week low of $35.24 and a 52 week high of $50.99. The firm has a market capitalization of $2,190.00, a price-to-earnings ratio of 22.44, a PEG ratio of 2.53 and a beta of 1.69. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.19 and a current ratio of 2.13.
Halyard Health (NYSE:HYH) last announced its earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.13. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The company had revenue of $401.40 million during the quarter, compared to analyst estimates of $394.54 million. During the same period last year, the company posted $0.48 earnings per share. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. analysts predict that Halyard Health, Inc. will post 2.08 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Halyard Health, Inc. (HYH) is Paradice Investment Management LLC’s 5th Largest Position” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://transcriptdaily.com/2017/11/28/halyard-health-inc-hyh-is-paradice-investment-management-llcs-5th-largest-position.html.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Want to see what other hedge funds are holding HYH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halyard Health, Inc. (NYSE:HYH).
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.